Nanjing Leads Biolabs Soars 122% on Hong Kong Debut Following HK$1.1 Billion IPO
核心洞察
Nanjing Leads Biolabs (搜索) shares surged 122% on its Hong Kong Stock Exchange trading debut after raising HK$1.1 billion through its IPO to fund immuno-oncology therapies.
The company's lead candidate LBL-024, a first-in-class bispecific antibody targeting PD-L1 (搜索) and 4-1BB (搜索), achieved a 75% overall response rate and 92.3% disease control rate in phase Ib/II trials for extrapulmonary neuroendocrine carcinoma (搜索).
LBL-024 has secured China's NMPA Breakthrough Therapy Designation and U.S. FDA Orphan Drug Designation, with a pivotal Phase III trial underway for first-line EP-NEC treatment.
Chinese biotech company Nanjing Leads Biolabs (搜索) Co., Ltd. (维立志生物) made a spectacular Hong Kong Stock Exchange debut, with shares soaring 122% following its HK$1.1 billion initial public offering. The strong market reception reflects investor confidence in the company's immuno-oncology pipeline, particularly its lead bispecific antibody program targeting rare cancers.
LBL-024 Drives Market Enthusiasm
The company's flagship asset, LBL-024, represents a first-in-class bispecific antibody targeting PD-L1 (搜索) and 4-1BB (搜索) for the treatment of extrapulmonary neuroendocrine carcinoma (搜索) (EP-NEC). This rare and aggressive cancer currently has no approved therapies, creating a significant unmet medical need.
In phase Ib/II clinical trials, LBL-024 demonstrated remarkable efficacy when combined with chemotherapy, achieving a 75% overall response rate (ORR) and 92.3% disease control rate (DCR). These results far exceed historical benchmarks for chemotherapy alone in this patient population.
The promising clinical data has attracted regulatory attention from both Chinese and U.S. authorities. LBL-024 secured China's NMPA Breakthrough Therapy Designation in October 2024 and received U.S. FDA Orphan Drug Designation in November 2024. These regulatory designations could accelerate the approval process and provide market exclusivity benefits.
Pivotal Phase III Trial Underway
Leads Biolabs is currently conducting a pivotal Phase III trial in China evaluating LBL-024 as a first-line treatment for EP-NEC. Success in this study could validate the company's bispecific platform technology and establish a foothold in a market with no existing approved therapies.
Diversified Oncology Pipeline
Beyond LBL-024, the company has developed a broad pipeline of bispecific antibodies and antibody-drug conjugates (ADCs) targeting multiple oncology indications. The portfolio includes treatments for solid tumors such as small cell lung cancer (搜索) (SCLC), ovarian cancer (搜索), and gastric cancer (搜索), as well as hematologic malignancies including multiple myeloma (搜索).
Key pipeline programs include LBL-007, a LAG-3 (搜索) inhibitor that has shown a 33.3% ORR in nasopharyngeal carcinoma (搜索) (NPC), a cancer particularly prevalent in Southeast Asia. Another notable candidate is LBL-034, a CD3 (搜索)/GPRC5D (搜索) bispecific antibody targeting relapsed multiple myeloma (搜索), which utilizes the company's LeadsBody™ platform for T-cell engagers.
Proprietary Technology Platforms
The company's competitive advantage stems from its proprietary X-Body™ and LeadsBody™ platforms, which enable the design of bispecific antibodies with optimized affinity ratios. These systems are designed to reduce toxicity while enhancing efficacy, addressing a technical challenge that has proven difficult for many competitors in the bispecific antibody space.
Strategic Partnerships and Global Expansion
Leads Biolabs has established strategic alliances to expand its capabilities and global reach. The company partnered with U.S.-based BiOneCure Therapeutics (搜索) to combine ADC expertise, pairing Leads' antibodies with BiOneCure's payload-linker technology. This collaboration aims to accelerate progress in solid tumor treatments within a market projected to reach $22 billion by 2030.
Additionally, the company formed a joint venture with Oblenio Bio (搜索) in 2024, signaling its commitment to AI-driven drug discovery as a strategic initiative to maintain competitive advantage.
Funding and Development Strategy
The HK$1.1 billion raised through the IPO will fund clinical trials, research and development activities, and manufacturing scale-up. The company has previously raised $163 million in financing rounds, including a Series C1 round completed in late 2024, demonstrating sustained investor interest in its platform and pipeline.
The successful IPO and strong debut performance occur against a backdrop of heightened volatility in the biotech sector during 2025, with investors closely scrutinizing clinical trial outcomes and regulatory developments. Leads Biolabs' focus on addressing unmet medical needs in rare cancers and its proprietary bispecific antibody technology appear to have resonated with investors seeking differentiated opportunities in the crowded immuno-oncology space.